| Literature DB >> 31010204 |
Chang Liu1,2, Yan Cui3, Fuwei Pi4,5, Yuliang Cheng6,7, Yahui Guo8,9, He Qian10,11.
Abstract
: Aloe vera is a medicinal plant species of the genus Aloe with a long history of usage around the world. Acemannan, considered one of the main bioactive polysaccharides of Aloe vera, possesses immunoregulation, anti-cancer, anti-oxidation, wound healing and bone proliferation promotion, neuroprotection, and intestinal health promotion activities, among others. In this review, recent advancements in the extraction, purification, structural characteristics and biological activities of acemannan from Aloe vera were summarized. Among these advancements, the structural characteristics of purified polysaccharides were reviewed in detail. Meanwhile, the biological activities of acemannan from Aloe vera determined by in vivo, in vitro and clinical experiments are summarized, and possible mechanisms of these bioactivities were discussed. Moreover, the latest research progress on the use of acemannan in dentistry and wound healing was also summarized in details. The structure-activity relationships of acemannan and its medical applications were discussed. Finally, new perspectives for future research work on acemannan were proposed. In conclusion, this review summarizes the extraction, purification, structural characteristics, biological activities and pharmacological applications of acemannan, and provides information for the industrial production and possible applications in dentistry and wound healing in the future.Entities:
Keywords: Aloe vera; acemannan; applications; biological activity; polysaccharide; structure
Mesh:
Substances:
Year: 2019 PMID: 31010204 PMCID: PMC6515206 DOI: 10.3390/molecules24081554
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Summary of the extraction, purification, characterization methods and structural studies of acemannan.
| Source | Extraction, Fractionation, Purification | Structural Characterization Method | MW (kDa) | Monosaccharide Composition | Structural Feature | Yield | Reference |
|---|---|---|---|---|---|---|---|
| Fresh gel | Water extraction (Homogenization, centrifugation mixed with 3 volumes of ethanol, lyophilization) | LC; FT-IR; SEC; 1H-NMR | 190–220 | Man: Glc: Gal = 57:22:17 | --- | [ | |
| Fresh gel | Water extraction; separation (Shodex Sugar KS-804 column) | 13C-NMR; SEM 1H-NMR; FT-IR | 150-190 | Man: Glc: Gal = 65:17:17 | Single-branched galactose at C6 of the second acetylated mannose residue | 0.04% | [ |
| Frozen gel | Ultrafiltration cell membrane (Fractionated by ultrafiltration cell with MW cut-off membrane) | HPLC (BIOSEP SECH400 column); GC (SP2330 glass-capillary column); 1H-NMR; IR | >500 | Man: Glc = 97:3 | Galp-(1→residues link to | 2% | [ |
| Fresh gel | Water extraction; separation (homogenization, centrifugation, alcohol precipitation, dialysis, lyophilization) | HPLC (Shodex Sugar KS-804 column); GC–MS; 13C-NMR | ≥800 | Man (77.18%); Glc (15.3%); Gal (4.9%); Ara (0.7%); Rha (0.2%); Fuc (0.34%); Xyl (0.7%) | β-(1→4) | 0.2% | [ |
| Fresh gel (1 year old) | Water extraction (Homogenization, centrifugation with 80% v/v alcohol, ammonium sulfate precipitation, lyophilization) | GC-MS; SEC; 13C-NMR | 1100 | Man: Glc = 15:1 | --- | [ | |
| Fresh gel | Water extraction; (Homogenization, centrifugation mixed with 3 volumes of ethanol, wash with ethanol, lyophilization) | HPGPC; FTIR; GLC-MS; TGA | 1020 | Mannose (84.9%): glucose (7.2%); galactose (3.9%) | (1→4)-Linked mannose/glucose | --- | [ |
| Frozen gel | Water extraction (Homogenization, centrifugation, alcohol precipitation, lyophilization) | GC–MS; Ion-chromatograph; 13C-NMR | 1100 | Man: Glc: Gal: GalA: Fuc: Ara: Xyl = 120:9:6:3:2:2:1 | →4)-β-Manp-(1→ and →4)-β-Glcp-(1→ residues in 15:1 ratio | --- | [ |
| Fresh gel (3 years old)) | Water extraction (Homogenization, centrifugation, supernatant mixed with 3 volumes of ethanol, pellet) | FACE; FT-IR; SEC | 281 | Man (62.9%); Glc (13.1%); Gal (0.6%) | --- | 1.7% | [ |
| Frozen gel | Water extraction; (depigmentation, deproteinization) | CR; GC-MS; PACE | --- | Man (86.87%); Glc (0.05%); Gal (12.68%); Ara (0.38%) | β-(1→4) | 0.32% | [ |
Fluorophore-assisted carbohydrate electrophoresis (FACE); Congo red (CR); Liquid chromatography (LC); Size exclusion chromatography(SEC); Polysaccharide analysis by carbohydrate gel electrophoresis (PACE); Thermogravimetric analysis (TGA).
Figure 1Schematic representation of extraction, separation purification and structure characterization of acemannan from Aloe vera.
Biological activity of acemannan in vitro.
| Source | Target | Dose | Biological Activities | Action or Mechanism | Reference |
|---|---|---|---|---|---|
| Fresh gel | Human gingival fibroblasts | 16 mg/mL | Oral wound healing | Proliferation (+); keratinocyte growth factor-1 (KGF-1) (+); VEGF (+); type I collagen production (+) | [ |
| Fresh gel | Human gingival fibroblasts | 10 mg/mL | Oral wound healing | IL-6 (+); IL−8 (+); p50/DNA (+); TLR5/NF-κB (+); Binds with TLR5 ectodomain flagellin recognition sites | [ |
| Freeze-dried gel | Immature dendritic cells (mice) | 100 µg/mL | Immunomodulatory | Induce maturation of immature DCs; mixed lymphocyte reaction; IL-12 (+) | [ |
| Fresh gel | Bone marrow stromal cell (BMSC) (rat) | 8 mg/mL | Periodontal tissue regeneration | BMSC proliferation (+); vascular endothelial growth factors (VEGF) (+); ALPase activity (+); bone morphogenic protein-2 (BMP-2) (+); bone sialoprotein (BSP) (+); osteopontin(OPN) (+); mineralization (+) | [ |
| Fresh gel | RAW 264.7 cells (mouse) | 100 µg/mL | Immunomodulatory | IL-6 (+); TNF-α (+); surface antigen expression (+); IFN-γ (+) | [ |
| Fresh gel | Tumoral cells (murine, human) | 0.6 mg/mL | Antitumor | Spontaneous proliferation (−); CD25 (+) | [ |
| Fresh gel | Peritoneal macrophages (mice) | 500 µg/mL | Induced tumor cell cytotoxicity | Endocytosis (+); murine macrophage stimulation | [ |
| Fresh gel | 3 g/L | Prebiotics | Growth (+); butyrate (+); propionate (+); SCFA (+) | [ | |
| Fresh gel | Hepatocytes (rat) | 0.4–250 µg/mL | Antigenotoxic | 3H]B[a]P-DNA adduct formation (−) | [ |
| Fresh gel | Human periodontal ligament cells | 4 mg/mL | Periodontal tissue regeneration | Cell proliferation (+); RUNX2 (+); GDF5(+); VEGF (+); BMP2 (+); COL1 (+); ALP (+); mineral deposition (+) | [ |
| Fresh gel | Human periodontal ligament cells, pulpal cells | 1 mg/mL | Periodontal regeneration | BMP2 mRNA (+) and protein (+) | [ |
| Fresh gel | Human primary dental pulpal cells | --- | Periodontal regeneration | Proliferation (+); alkaline phosphatase (+), type I collagen (+); BMP-2 (+); BMP-4 (+); vascular endothelial growth factor (+); dentin sialo protein expression (+); mineralization (+) | [ |
| LGM Pharma | Skin primary fibroblasts (mice) | 150 µg/mL | Cell proliferation | Cyclin D1 (+); eukaryotic translation initiation factor-4F (eIF4F) (+); activation of AKT/mTOR | [ |
Biological activity of acemannan in vivo.
| Source | Model | Target | Dose | Administraction | Biological Activities | Action or Mechanism | Reference |
|---|---|---|---|---|---|---|---|
| Fresh gel | --- | Sprague Dawley rats (male) | 2% | External application | Wound healing | Reduced oral wound areas | [ |
| Dring gel (200:1) | Implanted with sarcoma 180 cell | ICR mice | 1 mg/mouse | Injection | Antitumor | Exhibited macrophage-activating activity | [ |
| Fresh gel | Tooth extraction model | Sprague–Dawley rats (male) | 32 mg/kg | External application | Accelerating bone formation | Bone mineral density (+); tooth socket healing (+) | [ |
| Fresh gel | Irradiation at 2.14 Gy/min | Swiss albino mice (male) | 50 mg/kg | Oral gavage | Immunomodulation/radioprotection; antioxidation | Scavenge free radicals; survival (+); mitogenic activity (+); hematopoiesis (+); activation of MAPK | [ |
| Fresh gel | Radiation-induced mortality | Swiss albino mice (male) | 150 mg/kg | Oral gavage | Immunomodulatory | Survival (+); peripheral lymphocytes (+);TNF-α (+); IL-1 (+) | [ |
| Fresh gel | Radiation-induced myelosuppression | C57BL/6 mice (female) | 1 mg/mouse | Injection | Hematopoiesis | White blood cell (+); spleen cellularity (+); lymphocytes (+); neutrophils (+); monocytes | [ |
| Fresh gel | [3H]B[a]P | ICR mice (male) | 50 mg/mouse | Oral gavage | Antigenotoxic | Glutathione-s-transferase (+);[3H]B[a]P-DNA adduct formation (-) | [ |
| Fresh gel | --- | Mongrel Dogs | --- | Oral gavage | Accelerating bone formation | Induced bone, cementum, and periodontal ligament formation | [ |
| Fresh gel | Full-thickness skin excisional wound | BALB/c mice (male) | 2 mg/kg | Injection | Wound healing | Accelerated skin wound closure | [ |
| Fresh gel | --- | SpragueeDawley rats (female) | 8 mg/sponge | External application | Bone regeneration | Integrate new bone with the old bone | [ |
Figure 2Pharmacological effects of acemannan in vitro and in vivo.
Figure 3Application of acemannan in dentistry and wound healing.
Figure 4Acemannan induction of IL-6/-8 expression and p50/DNA binding in gingival fibroblasts via TLR5/ / NF-κB-dependent signaling pathway.